Bemnifosbuvir-Ruzasvir + Sofosbuvir-Velpatasvir
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HEPATITIS C VIRUS CHRONIC INFECTION
Conditions
HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
Trial Timeline
Jun 2, 2025 → Mar 1, 2027
NCT ID
NCT07037277About Bemnifosbuvir-Ruzasvir + Sofosbuvir-Velpatasvir
Bemnifosbuvir-Ruzasvir + Sofosbuvir-Velpatasvir is a phase 3 stage product being developed by Atea Pharmaceuticals for HEPATITIS C VIRUS CHRONIC INFECTION. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07037277. Target conditions include HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07037277 | Phase 3 | Recruiting |
Competing Products
20 competing products in HEPATITIS C VIRUS CHRONIC INFECTION
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| Pegasys® + Pegasys® | Chugai Pharmaceutical | Approved | 85 |
| peginterferon alfa-2a + rivavirin | Chugai Pharmaceutical | Phase 3 | 77 |
| SOF + COPE | Chugai Pharmaceutical | Pre-clinical | 23 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK788 | Astellas Pharma | Phase 2 | 52 |
| MK-2248 | Merck | Phase 1 | 33 |
| Interferon alfacon-1 | Astellas Pharma | Phase 3 | 77 |
| Pegylated Interferon + Ribavirin | Astellas Pharma | Approved | 85 |
| Tacrolimus + steroids, monoclonal anti-IL2R antibody | Astellas Pharma | Phase 2 | 52 |
| Dolutegravir + Rlipivirine + GSK1265744 | Shionogi | Phase 1 | 33 |
| Dolutegravir + Methadone | Shionogi | Phase 1 | 33 |
| Clevudine + Adefovir | Eisai | Phase 3 | 77 |